USP33 Antibody

What is USP33 and what applications are USP33 antibodies validated for?

USP33, also known as KIAA1097 or VDU1, belongs to the peptidase C19 family and functions as a deubiquitinating enzyme. Commercial USP33 antibodies have been validated for multiple applications with specific dilution recommendations:

The antibody choice should be based on your specific experimental design and the application required .

What is the expected molecular weight of USP33 and how should band patterns be interpreted?

USP33 has a calculated molecular weight of 107 kDa (942 amino acids), though observed molecular weights can vary:

• 107 kDa (full-length protein)

• 103 kDa (commonly observed variant)

• 93 kDa (additional band sometimes observed)

When performing Western blot analysis, these multiple bands may represent different isoforms or post-translational modifications. Validation experiments comparing control and USP33 knockdown samples can confirm band specificity .

What tissues and cell lines are recommended as positive controls for USP33 antibody validation?

Based on published literature and commercial validation data, recommended positive controls include:

Cell lines:

• HEK-293 cells (high endogenous expression)

• HeLa cells (moderate expression)

• U2OS cells (for immunofluorescence studies)

Tissue samples:

• Mouse brain tissue (for WB)

• Human prostate tissue (normal and cancer)

• Human kidney tissue

When optimizing a new USP33 antibody, running parallel experiments with known positive controls is essential for proper validation .

What antigen retrieval methods are recommended for USP33 IHC staining?

For optimal USP33 detection in formalin-fixed, paraffin-embedded (FFPE) tissues:

Primary recommendation: TE buffer pH 9.0

Alternative method: Citrate buffer pH 6.0

The immunohistochemistry protocol typically involves:

• Deparaffinization and rehydration of 5-micron sections

• Antigen retrieval by heating in buffer for 20 minutes in a microwave

• Blocking endogenous peroxidase with 3% hydrogen peroxide (10 minutes)

• Blocking with goat serum (30 minutes)

• Overnight incubation with primary USP33 antibody at 4°C

• Detection with biotinylated secondary antibody and visualization with DAB staining

For scoring, the IRS (Immunoreactive Score) system can be used, considering both staining intensity (0-3) and percentage of positive cells (0-4) .

How can USP33-protein interactions be effectively studied using co-immunoprecipitation?

Co-immunoprecipitation is a valuable approach for studying USP33 interactions with binding partners such as Robo1, RALB, and TGFBR2. Based on published methods:

Recommended protocol:

• Prepare cell lysates 48-72 hours post-transfection using a mild lysis buffer (0.5% NP-40, 50 mmol/L Tris [pH 7.5], 150 mmol/L NaCl, 1 mmol/L EDTA, with protease inhibitors)

• Clear lysates by centrifugation (14,000 rpm, 10 min, 4°C)

• Pre-clear with protein A/G beads if needed

• Incubate lysates with 2-5 μg of specific antibody overnight at 4°C

• Add protein A/G beads for 2-4 hours

• Wash 4-5 times with lysis buffer

• Elute proteins with SDS sample buffer and analyze by Western blotting

Important considerations:

• For detecting endogenous interactions, crosslinking may be required

• Both N-terminal and C-terminal tags on USP33 have been successfully used (HA, FLAG, GFP)

• Controls should include IgG control antibody and USP33 knockdown samples

This approach has successfully identified interactions between USP33 and various proteins, including Robo1, β2-adrenergic receptor, and RALB .

What are the methodological considerations for studying USP33's deubiquitinating activity?

To study the deubiquitinating activity of USP33 on target proteins:

Deubiquitination assay protocol:

• Transfect cells with vectors expressing the substrate protein (e.g., RALB, TGFBR2) and HA-tagged ubiquitin

• Include conditions with wild-type USP33 overexpression and catalytically inactive USP33 mutant

• Treat cells with proteasome inhibitor (MG132, 10 μM) for 4-6 hours before lysis

• Lyse cells in denaturing conditions (1% SDS, heat treatment) followed by dilution

• Immunoprecipitate the substrate protein

• Analyze ubiquitination status by immunoblotting with anti-HA antibody

Critical controls:

• Catalytically inactive USP33 mutant (C-to-S mutation in catalytic domain)

• USP33 knockdown samples

• Comparison with related deubiquitinase USP20 (when appropriate)

The deubiquitinating activity of USP33 has been demonstrated for multiple substrates, including RALB (affecting interaction with exocyst proteins) and β2-adrenergic receptor (affecting receptor recycling) .

How can researchers assess USP33 expression changes across cancer types and their prognostic significance?

For comprehensive analysis of USP33 expression in cancer:

Recommended multi-level approach:

• mRNA expression analysis:

  • Quantitative RT-PCR using validated primers

  • Analysis of public databases (TCGA, Oncomine, cBioPortal)

  • Compare matched tumor vs. adjacent non-tumor tissues

• Protein expression analysis:

  • Immunohistochemistry with proper scoring system

  • Western blot of tissue lysates

  • Tissue microarray analysis for high-throughput screening

• Prognostic significance assessment:

  • Kaplan-Meier survival analysis stratifying patients by USP33 expression

  • Multivariate analysis with clinical parameters

  • Correlation with specific cancer subtypes or stages

Research findings across cancer types:

• Lung cancer: Decreased expression in multiple cohorts; lower expression correlates with poor prognosis

• Pancreatic cancer: Increased expression; high levels correlate with poor prognosis

• Esophageal cancer: Altered expression affects cancer cell migration through integrin α6

• Other cancers: Altered expression in breast cancer, melanoma, and acute myeloid leukemia

This methodological framework allows for comprehensive characterization of USP33's role across different cancer contexts .

How can USP33 knockdown/knockout models be generated and validated for functional studies?

For manipulating USP33 expression in experimental systems:

siRNA/shRNA-mediated knockdown:

• Multiple targeting sequences have been validated (labeled as USP33-1, USP33-2)

• Recommended transfection time: 72 hours before analysis

• Validation by Western blot showing >80% reduction in protein expression

• Important to assess potential compensation by USP20 due to functional redundancy

CRISPR/Cas9 knockout approach:

• Design guide RNAs targeting early exons

• Verify editing by sequencing and protein loss by Western blot

• Generate multiple clonal lines to avoid off-target effects

• Consider conditional knockout systems for essential functions

Rescue experiments:

• Generate RNAi-resistant USP33 constructs with silent mutations

• Clone into expression vectors with appropriate promoters (e.g., CMV)

• Deliver via transfection or retroviral transduction

• Compare wild-type USP33 with catalytically inactive mutant in rescue experiments

These approaches have been successful in elucidating USP33 functions in multiple cellular contexts .

What are the best practices for studying USP33 subcellular localization?

USP33 exhibits distinct subcellular localization patterns that can be critical for its function:

Immunofluorescence protocol optimization:

• Fixation: 4% paraformaldehyde (10 min) for membrane preservation

• Permeabilization: 0.1-0.2% Triton X-100 (5-10 min)

• Blocking: 5% BSA or normal serum (1 hour)

• Primary antibody: USP33 antibody (1:50-1:500, overnight at 4°C)

• Secondary antibody: Fluorophore-conjugated anti-rabbit (1:500-1:1000)

• Nuclear counterstain: DAPI

• Mounting: Anti-fade medium

Key observations from published studies:

• USP33 localizes to perinuclear regions and cytoplasmic vesicles

• In some cells, USP33 can be detected at the plasma membrane

• Upon stimulation (e.g., with receptor agonists), USP33 may relocalize to envelop receptor-containing vesicles

• USP33 localization is broadly confined to the secretory pathway, particularly endoplasmic reticulum-associated structures

Co-localization studies:

• Markers for ER, Golgi, endosomes can define precise localization

• Co-staining with interaction partners (e.g., Robo1, β2AR) can reveal functional complexes

These approaches have successfully characterized USP33 localization in multiple cell types .

How can researchers investigate USP33's role in Slit-Robo signaling pathways?

USP33 plays a critical role in Slit-Robo signaling, particularly in cell migration:

Experimental approach for studying this pathway:

• Protein-protein interaction analysis:

  • Co-immunoprecipitation of USP33 with Robo1

  • Yeast two-hybrid screening to identify additional components

  • Mapping interaction domains through truncation mutants

• Functional migration assays:

  • Dunn chamber chemotaxis assays with SDF1 gradient

  • Wound healing/scratch assays

  • Transwell migration assays

  • 3D invasion assays in matrices

• Slit responsiveness experiments:

  • Treatment with Slit preparation vs. mock control

  • Compare wild-type cells with USP33 knockdown/knockout

  • Rescue experiments with wild-type vs. catalytically inactive USP33

Key findings:

• USP33 binds directly to Robo1 receptor

• USP33 is required for Slit responsiveness in cancer cells

• Slit treatment inhibits breast cancer cell migration, but this effect is lost in USP33-depleted cells

This methodological framework has successfully elucidated USP33's role in the Slit-Robo pathway in multiple cancer contexts .

What methods can be used to study USP33's role in regulating RALB functions and exocyst complex formation?

USP33 regulates RALB's interactions with different components of the exocyst complex:

Recommended experimental approaches:

• RALB activity assessment:

  • RALBP1-RBD binding assays to measure active RALB

  • Compare control vs. USP33 knockdown/overexpression

• RALB-exocyst component interaction studies:

  • Co-immunoprecipitation of RALB with SEC5 or EXO84

  • USP33 overexpression or knockdown conditions

  • MAPPIT assay for verification of interactions

  • Immunofluorescence co-localization studies

• Ubiquitination analysis:

  • Co-expression of RALB with HA-tagged ubiquitin

  • Purification by metal affinity chromatography

  • Site-directed mutagenesis of key lysine residues (e.g., K47 in RALB)

  • Analysis of RALB ubiquitination status under different conditions

Key findings:

• USP33 does not affect RALB activation state

• USP33 switches RALB binding from SEC5 to EXO84

• USP33 depletion enhances RALB-SEC5 interaction while inhibiting RALB-EXO84 interaction

• RALB ubiquitination at K47 controls interactions with exocyst proteins

This experimental framework has elucidated USP33's role as a molecular switch in RALB signaling .

How can researchers investigate USP33's function in regulating β2-adrenergic receptor recycling?

USP33 and its homolog USP20 coordinate β2-adrenergic receptor (β2AR) recycling through deubiquitination:

Experimental approach:

• Receptor ubiquitination analysis:

  • Stimulate cells with isoproterenol (Iso)

  • Immunoprecipitate β2AR and detect ubiquitination

  • Compare control vs. USP33 overexpression conditions

• Receptor recycling assays:

  • Downregulate surface receptors with 6-hour Iso treatment

  • Perform agonist washout to allow recycling

  • Measure cell-surface receptors by radioligand binding (3H-CGP12177)

  • Compare between control, USP33 overexpression, and USP33/USP20 knockdown conditions

• Receptor trafficking visualization:

  • Fluorescently-tagged β2AR

  • Live-cell imaging during agonist stimulation and washout

  • Co-localization with USP33 and endosomal markers

Key findings:

• USP33 overexpression diminishes β2AR ubiquitination

• Single knockdown of either USP33 or USP20 has minimal effect on receptor recycling

• Double knockdown of both USP33 and USP20 completely inhibits receptor recycling

• In stimulated cells, β2AR-positive vesicles can be observed being enveloped by USP33-positive vesicles

This methodological approach has successfully characterized the redundant but essential roles of USP33 and USP20 in β2AR recycling .

How can researchers optimize USP33 antibody conditions for challenging tissue samples?

For optimal USP33 detection in difficult samples:

Optimization strategies:

• Antigen retrieval variations:

  • Extended retrieval time (30-40 minutes)

  • Higher temperature protocols

  • Alternative buffers (Tris-EDTA vs. citrate)

  • Enzymatic retrieval (proteinase K) as last resort

• Signal amplification approaches:

  • Tyramide signal amplification (TSA)

  • Polymer-based detection systems

  • Biotin-free detection to reduce background

• Antibody optimization:

  • Titration series (1:20 to 1:1000)

  • Extended primary antibody incubation (overnight to 48 hours at 4°C)

  • Addition of protein carriers (BSA, casein)

  • Detergent optimization (0.1-0.3% Triton X-100 or Tween-20)

• Background reduction:

  • Additional blocking steps with 5% milk or commercial blockers

  • Pre-adsorption of secondary antibodies

  • Avidin/biotin blocking for biotin-based detection systems

These approaches have been successful for detecting USP33 in various challenging samples, including cancer tissues with variable fixation conditions .

What strategies can resolve discrepancies in USP33 expression patterns between different experimental methods?

When facing contradictory results about USP33 expression:

Systematic troubleshooting approach:

• Verify antibody specificity:

  • Validate with positive and negative controls

  • Use multiple antibodies targeting different epitopes

  • Perform antibody validation with knockdown/knockout samples

• Compare mRNA vs. protein levels:

  • qPCR with validated primers and reference genes

  • Northern blot for mRNA size verification

  • Western blot with antibodies against different epitopes

  • Consider post-transcriptional regulation

• Assess methodology-specific confounders:

  • For IHC: fixation artifacts, antigen masking, different scoring methods

  • For WB: protein extraction efficiency, post-translational modifications

  • For qPCR: primer efficiency, splice variant detection

• Investigate biological explanations:

  • Tissue heterogeneity and cellular composition differences

  • Isoform expression variations

  • Post-translational modifications affecting antibody recognition

  • Disease-specific alterations in protein stability

This systematic approach helps reconcile apparently contradictory findings, as seen in studies of USP33 in different cancer types where both up- and down-regulation have been reported .

How can USP33 protein degradation mechanisms be studied experimentally?

To investigate USP33 turnover and regulation:

Experimental approaches:

• Protein stability assessment:

  • Cycloheximide chase experiments (protein synthesis inhibition)

  • Comparison of USP33 half-life under different conditions

  • Analysis with proteasome inhibitors (MG132) or lysosome inhibitors (chloroquine)

• Ubiquitination analysis:

  • USP33 immunoprecipitation followed by ubiquitin detection

  • Ubiquitin mutants to characterize chain types (K48, K63, etc.)

  • In vitro ubiquitination assays with purified components

• E3 ubiquitin ligase identification:

  • Mass spectrometry to identify USP33-interacting proteins

  • RNA interference screening of candidate E3 ligases

  • Co-immunoprecipitation validation of interactions

  • In vitro reconstitution of ubiquitination

Key findings:

• p97 (VCP) and its adaptor complex Ufd1-Npl4 are critical for USP33 degradation

• The E3 ubiquitin ligase HERC2 targets USP33 for degradation

• p97 inhibition (with NMS-873) or knockdown blocks USP33 degradation

• USP33 is regulated post-translationally rather than transcriptionally

This approach has successfully characterized the HERC2/p97 pathway as a key regulator of USP33 levels .

What are the considerations for multiplex analysis of USP33 with other markers?

For simultaneous detection of USP33 with other proteins:

Multiplex immunofluorescence optimization:

• Antibody compatibility assessment:

  • Host species selection to avoid cross-reactivity

  • Isotype selection for secondary antibody discrimination

  • Sequential vs. simultaneous staining protocols

• Signal separation strategies:

  • Fluorophore selection with minimal spectral overlap

  • Linear unmixing for overlapping fluorophores

  • Sequential scanning for confocal microscopy

  • Quantum dots for narrow emission profiles

• Validated marker combinations:

  • USP33 + Robo1 (for migration studies)

  • USP33 + β2AR (for receptor recycling)

  • USP33 + RALB + exocyst components (SEC5, EXO84)

  • USP33 + organelle markers (calnexin for ER, LAMP1 for lysosomes)

• Controls for multiplexed detection:

  • Single-stained controls for spectral overlap assessment

  • Secondary-only controls for background evaluation

  • Isotype controls for non-specific binding

  • Absorption controls with excess antigen where available

This approach has been successful in characterizing USP33's co-localization with various binding partners and its dynamic subcellular distribution in response to stimuli .

How should researchers interpret varied USP33 expression patterns across cancer types?

The context-dependent role of USP33 in different cancers requires careful interpretation:

Analytical framework:

• Comprehensive expression profiling:

  • Multiple patient cohorts (>3 independent datasets)

  • Paired tumor/normal samples when possible

  • Multiple methodologies (IHC, WB, qPCR)

  • Subtype-specific analysis

• Downstream target assessment:

  • Correlation with known USP33 substrates (RALB, Robo1, TGFBR2)

  • Pathway activation status (TGF-β, Slit-Robo)

  • Integration with public omics data

• Functional validation:

  • Cell type-specific knockdown/overexpression

  • Cancer-specific functional readouts

  • Patient-derived models

  • In vivo validation where possible

Contrasting expression patterns observed:

• Downregulated in lung cancer: Correlates with poor prognosis; may function as tumor suppressor through Slit-Robo pathway

• Upregulated in pancreatic cancer: Promotes malignant phenotype through TGF-β signaling; forms positive feedback loop with ZEB1

• Role in esophageal cancer: Promotes migration through integrin α6 deubiquitination

This analytical framework helps reconcile apparently contradictory findings and emphasizes USP33's context-dependent functions in cancer biology .